1 KRBL share price target reports by brokerages below. See what is analyst's view on KRBL share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
The strong balance sheet and consistency in strong operating performance makes stock value buy but then caution needed to be exercised till the name of the company is absolved from all kinds of charges. We have valued the stock at PE 12x of FY21 EPS (giving discount to 5 years average PEx of 14.8) and have arrived at the TP of Rs. 290 with 29% potential upside. Key risks to valuation are growing concerns on pesticide residue issue and reduced import demand from Iran following economic sanctions imposed by the USA.
Given the staple food status of basmati rice in Middle East region, its demand continues to be strong there. We believe that KRBL with great brand recall and huge penetration in the region (which accounts for 80% of export from the company), it is well positioned to capitalize on the opportunities. Moreover, increasing trend of basmati consumption demand in domestic market, augurs well for the company with 36% of domestic market share. We value the stock at PE 15.9x of FY21 EPS which gives TP of Rs. 403 with potential upside of 18%. Risk to valuation could be escalating of pesticide issue in Saudi Arabia and Europe.
The company has been able to maintain sales and realization growth momentum and is expected continue to do so on the back of brand strength, market reach and right product-mix. The company has a healthy balance sheet with surplus cash invested in inventory. However, recent overhang created by serving of Demand Notice by Income Tax department calls for caution to be exercised on stock. We have valued the stock at 5 years average PE 13.1x of FY21E EPS and have arrived at target price of Rs. 331 with 5% potential upside. We recommend “HOLD” on stock.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.